Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:3/26/2009

fibromyalgia) product candidate. Lower expenses in the fourth quarter of 2008 also reflect a reduced level of activity on development programs other than JZP-6, pending partnering or other funds to pursue future development of those programs.

Selling, general and administrative expenses for the quarter ended December 31, 2008 were $20.2 million, compared to $28.0 million for the quarter ended December 31, 2007. For the year ended December 31, 2008, selling, general and administrative expenses were $111.4 million, compared to $78.5 million for the year ended December 31, 2007. The increase in 2008 was primarily due to spending in connection with launch activities for LUVOX CR, including increased headcount and higher expenses to support the company's expanded sales force. The decrease in the fourth quarter of 2008 reflects a decrease in spending on LUVOX CR and reductions in headcount.

Jazz Pharmaceuticals' net loss for the quarter ended December 31, 2008 was $56.9 million, compared to a net loss of $60.0 million for the quarter ended December 31, 2007. For the year ended December 31, 2008, the net loss was $184.3 million, compared to a net loss of $138.8 million for the year ended December 31, 2007. Expenses for 2008 included a fourth quarter non-cash impairment charge of $29.8 million relating to the company's LUVOX CR intangible asset. Expenses for 2007 included a fourth quarter non-cash impairment charge of $20.2 million relating to the company's Antizol(R) (fomepizole) intangible asset; the rights to that product were sold to a third party during the third quarter of 2008. Net loss for 2008 also included increased interest expense, as compared with 2007, due primarily to the issuance of $40.0 million of additional senior secured notes in March 2008. Net loss for 2007 included a $17.5 million provision for the previously disclosed settlement of a government investigation of Orphan Medical.

Jazz Pharmaceuticals'
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 DePuy Pinnacle ... DePuy Pinnacle Hip Replacement System continue to move forward ... Bernstein Liebhard LLP reports. According to an Order ... to produce monitoring reports associated with a 2007 criminal ... device marketing practices. Plaintiffs maintained in their ...
(Date:5/22/2013)... 22, 2013 Today, Zane Benefits, Inc. ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution plans and ... Benefits’ website, beginning in 2014 as part of the ... and small businesses will become available through new state ...
(Date:5/22/2013)... that hospitals may be reaping enormous income for ... bloodstream infections contracted in their intensive care units. ... in the American Journal of Medical Quality ... who develops an avoidable central line-associated bloodstream infection ... for than a similar infection-free patient. Moreover, hospitals ...
(Date:5/22/2013)... 2013 Registered Dietitian and Founder of Tatalou ... Tatalou.com sharing a recipe for making energy bars at home. ... Bars ,” takes a recipe modified from one recently ... “Every day it gets more and more difficult to understand ... “The size of the nutrition label continues to grow and ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Unknown to the ... area at 30 mph. Minutes before it struck, the ... the nearing threat. This gave them time to reach safety ... Data is proud to provide a product that will ... A Wheelock SAFEPATH® SP40S Emergency Evacuation System provides ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2
... Feb. 20 /Xinhua-PRNewswire/ -- Venture Global Limited,unveils the ... pollution. With VEGO Power Blocker, cellphone users could ... Be Protected, VEGO Power Blocker Kills the Invisible ... VEGO Power Blocker is a piece of ultra-thinned ...
... first scientific evidence that deadly emerging diseases have ... the outbreaks main sources. They say new diseases ... the greatest threat to humans. Expansion of humans ... with wildlife are the reason, they say. Meanwhile, ...
... Anti-bleeding agent Trasylol tied to increased death, complications, studies ... new studies confirm an increased incidence of death and ... used to reduce bleeding during coronary artery bypass surgeries. ... over both the short- and long-term. , Trasylol,s German ...
... , , WEDNESDAY, Feb. 20 (HealthDay News) -- The time of day ... the difference between life and death. , Two new studies find ... weekends are more likely to die in the hospital than those ... acceptable, one researcher said. "We should not be treating patients ...
... heart disease had no ... risk factors, BALTIMORE, Feb. 20 In an effort to ... Foundation will,hold its annual Women,s Heart Health Fair on Tues., Feb. ... Mayor Sheila,Dixon has granted non-essential female workers two hours leave that ...
... put an end to toothaches, PHILADELPHIA, Feb. ... model, based in Philadelphia, announced that it is,expanding ... offering licensing,opportunities to qualifying dental practices, worldwide. This ... in advancing,affordable dental/health care available everywhere, to all., ...
Cached Medicine News:Health News:Venture Global Limited Introduces an Innovative Anti-Cellphone Radiation Sticker Named 'VEGO Power Blocker' 2Health News:Scientists make first map of emerging-disease hotpsots 2Health News:Scientists make first map of emerging-disease hotpsots 3Health News:More Evidence of Danger From Heart Surgery Drug 2Health News:More Evidence of Danger From Heart Surgery Drug 3Health News:In-Hospital Stroke Deaths Rise on Nights, Weekends 2Health News:In-Hospital Stroke Deaths Rise on Nights, Weekends 3Health News:Free Health Screenings Aim to Identify Risk of Heart Disease in Women 2Health News:Emergency Dentist 24/7(TM) Announces Worldwide Licensing Program 2
(Date:5/22/2013)... and MUNICH , May 22, 2013 /PRNewswire/ ... marketer of transcatheter aortic valve implantation (TAVI) systems for the ... results of the J enaValve Eval U ation of ... Pa T ients with S E vere Ao R tic ... . JUPITER is a post-market registry to evaluate five-year long ...
(Date:5/22/2013)... 2013  Milliman, Inc., a premier global consulting and ... Milliman Medical Index (MMI), which measures the healthcare costs ... benefits through an employer-sponsored preferred provider organization (PPO) plan. ... 2013 is $22,030. "For the second ... a percentage basis was the lowest in the history ...
(Date:5/22/2013)... WALLINGFORD, Conn. , May 22, 2013 ... announced today it has launched the first-ever line of ... Medical Services. The line includes QuikClot ® EMS ... and QuikClot ® EMS Rolled Gauze™, all custom-designed ... alive until they can be transported to a hospital ...
Breaking Medicine Technology:First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index 2Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2
... MORRISTOWN, N.J. , May 4 Sagent Pharmaceuticals, ... leading global generic pharmaceutical manufacturer, have launched an exclusive collaboration to ... the United States . , ... Under the agreement, Actavis will develop, obtain U.S. ...
... Provides Significantly Better Pain Relief Compared to Component Doses; Study Goals and ... , , ... 4 QRxPharma (ASX: QRX and OTCQX: QRXPY) announced ... IR, an immediate-release Dual-Opioid pain therapy.  Required for New Drug Application (NDA) ...
Cached Medicine Technology:Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products 2Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products 3QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 2QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 3QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 4QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: